CLINICAL TRIALS PROFILE FOR ESTRADIOL VALERATE

All Clinical Trials for ESTRADIOL VALERATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00293059 ↗	Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding	Completed	Bayer	Phase 3	2005-12-01	The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.
NCT00307801 ↗	Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding	Completed	Bayer	Phase 3	2006-02-01	The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.
NCT00335218 ↗	Fat Distribution in Healthy Early Postmenopausal Women	Completed	Bayer	Phase 4	2002-07-01	The aim of this study is to explore the effects of hormone replacement therapy with EV/DNG on abdominal fat distribution measured by magnetic resonance imaging.
NCT00463450 ↗	Efficacy of Gynodian® Depot in Women With Impaired Well-being	Completed	Ecron Acunova GmbH	Phase 3	2002-05-01	The typical menopausal symptoms that are associated with a variety of physical and psychological changes (e.g. nervousness, anxiety, and depression) and also with impaired sexual interest and enjoyment are caused by a lack of estrogen, a female sex hormone produced inside the body. To treat these symptoms, women who are postmenopausal can receive a therapy called 'hormone replacement therapy' (the dosage of hormones to replace the body's deficient hormones), for instance, with estrogen preparations injected into a muscle.In women with a uterus estrogen use causes the lining of the womb (endometrium) to grow (thicken) as before the menopause. With long-term use this may lead to pathological changes of the endometrium. That is why this therapy should be complemented by the estrogens' natural counterbalance, progesterone (progestogen), at a certain interval. This causes the lining of the womb to shed, with monthly bleeding like a normal period, thus avoiding excessive endometrial growth.Estrogen treatment is well known to relieve psychological complaints. The combination of an estrogen with a weak androgen (in this case Dehydroepiandrosterone (DHEA)) is presumed to clearly increase this effect. The present clinical study is to prove that Gynodian? Depot as a combination of estrogen and androgen has a better effect on psychological complaints and sexuality in postmenopausal women than has treatment with the estrogen Estradiol valerate alone.All patients will receive the same therapy, but differing in sequence. Either they receive Gynodian? Depot during the first five cycles and the estrogen-only preparation during cycles 6-10 (treatment group 1) or they receive the study medication in reverse order (treatment group 2). Patients will be assigned to one of the two groups at random. In either case they will be given an injection into the gluteal muscle every four weeks.Women with an intact uterus, in addition to the injections (the day of the injection being the 1st day of a cycle) have to take a tablet containing 5 mg Medroxyprogesterone acetate (MPA) (progestogen) per day for 14 days (cycle days 15-28) to enable the endometrium to shed in a monthly period.The study will extend over a total period of about 11 months, during which the patient will have 16 appointments for examinations.After patient has signed on the informed consent form for participation in this clinical study, the investigator will ask her, which diseases she has at the moment or has had during the past 12 months and which medicinal products she has been taking. Subsequently, she will have a gynecological examination (including the breasts) as well as a general physical examination. Blood pressure, heart rate as well as body height and weight will be measured and noted down. In addition, the doctor will question her about physical and psychological menopausal complaints by means of two different, short questionnaires. Only if the evaluation of these two questionnaires shows that she is eligible for the participation in this clinical study, will the following actions be carried through.Approx. 40 ml blood will be taken from the patient for a thorough laboratory test including her hormone levels, and she will be asked for a urine sample. Additionally, she will have a vaginal ultrasound examination of the womb lining, a cervical smear test (unless already done during the last three months), and an x-ray examination of the breasts (mammography) (unless already done during the last 12 months).These measures will be repeated at Final visit.About 3 weeks after visit 1, when the investigator has the results of all tests prescribed at visit 1, the patient will be asked to appear for visit 2.If the patient is eligible for a participation in this clinical study, she will be given the first injection of the study medication.During the following visits, injections will be given, blood pressure and pulse rate as well as body weight will be measured and blood will be drawn to measure the hormone levels.All procedures will apply also during the second treatment period. When switching to the second treatment period a physical and gynecological examination will additionally be performed.Questionnaires have to be filled in by the patient at different time points during the study.

Clinical Trial Conditions for ESTRADIOL VALERATE

Condition Name

Condition Name for ESTRADIOL VALERATE
Intervention	Trials
Infertility	25
Contraception	5
Infertility, Female	4
IVF	3

Condition MeSH

Condition MeSH for ESTRADIOL VALERATE
Intervention	Trials
Infertility	31
Infertility, Female	6
Polycystic Ovary Syndrome	4
Metrorrhagia	3

Clinical Trial Locations for ESTRADIOL VALERATE

Trials by Country

Trials by Country for ESTRADIOL VALERATE
Location	Trials
China	24
United States	21
Germany	20
Egypt	16
Australia	11

Trials by US State

Trials by US State for ESTRADIOL VALERATE
Location	Trials
Texas	1
Tennessee	1
South Dakota	1
South Carolina	1
Pennsylvania	1

Clinical Trial Progress for ESTRADIOL VALERATE

Clinical Trial Phase

Clinical Trial Phase for ESTRADIOL VALERATE
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	22
Phase 3	14

Clinical Trial Status

Clinical Trial Status for ESTRADIOL VALERATE
Clinical Trial Phase	Trials
Completed	41
Recruiting	11
Unknown status	10

Clinical Trial Sponsors for ESTRADIOL VALERATE

Sponsor Name

Sponsor Name for ESTRADIOL VALERATE
Sponsor	Trials
Bayer	12
Cairo University	5
Royan Institute	3

Sponsor Type

Sponsor Type for ESTRADIOL VALERATE
Sponsor	Trials
Other	73
Industry	18
UNKNOWN	2

ESTRADIOL VALERATE Market Analysis and Financial Projection

Last updated: April 28, 2026

Estradiol Valerate: Clinical-Stage Update, Market Analysis, and Forward Projection

What is the current clinical development status for estradiol valerate (EV)?

Estradiol valerate is an established estrogen ester with long clinical history in multiple geographies. Across major registries and published literature, EV is used primarily as an approved hormone therapy rather than as a modern “platform” pipeline candidate. As a result, the relevant “clinical trials update” for EV is less about breakthrough late-stage readouts and more about ongoing periodic studies tied to formulation, regimen optimization, and comparative safety/efficacy within existing standards of care.

Clinical-trials pattern observed for EV

In practice, EV trial activity typically clusters into:

• Regimen comparisons (dose schedules, switching strategies)
• Formulation studies (bioequivalence, release profile, route optimization)
• Contraception/menstrual indication studies in historical cohorts (where EV appears as a component, often in combination products)

What this means for an investment-grade readout

• EV does not behave like a late-stage pipeline asset with frequent, decision-critical Phase 3 readouts.
• The actionable “update” is therefore dominated by regulatory and market dynamics (competition from other estradiol esters, transdermal estradiol, and estradiol combinations), not by a concentrated stream of pivotal trials.

Key point: For business planning, EV should be treated as a commercial incumbent with incremental clinical activity, not as a driver of near-term clinical de-risking events.

How does estradiol valerate monetize today and what is the competitive map?

EV’s commercial footprint is largely defined by:

• Hormone replacement therapy (HRT) in menopausal symptoms
• Gender-affirming hormone therapy (GAHT) in some markets (where injectable or oral estrogen esters are used, depending on national guidance and product availability)
• Combination products in contraception contexts where EV is used with progestins (market-dependent)

Competitive set (practical substitution risk)

EV faces substitution primarily from:

• Transdermal estradiol (patches, gels), which tends to win on tolerability and thromboembolism profile narrative in many guideline environments
• Oral micronized estradiol and other estradiol esters (including estradiol hemisuccinate in some injectable formats)
• Estradiol + progestin combinations where the dominant product is the combination rather than EV itself

Where EV holds an advantage

EV can retain share where:

• Injectable estradiol esters match clinician and patient workflows
• Local pricing and reimbursement support older standards of care
• Supply continuity exists for EV-branded generics

Barriers to capturing incremental market share

• Clinical preference migration toward transdermal routes in multiple settings
• Guideline tightening around estrogen-only therapy and risk stratification
• Generic substitution pressure once exclusivity ends

What do market indicators imply for the next 3 to 5 years?

Because EV is an older, widely marketed estrogen ester, market projections are best anchored on category dynamics for estradiol and HRT use, plus route shifts within estrogen delivery.

Base-case projection framing

EV demand typically tracks:

• Menopausal symptom prevalence and HRT access (driven by demographics)
• Physician prescribing patterns by route (injectable/oral vs transdermal)
• Reimbursement and formulary composition
• Competitive penetration by transdermal estradiol brands and generics

Route-shift effect (directional)

• Transdermal estradiol has structural demand support in many markets due to patient-perceived convenience and clinician comfort on risk messaging.
• EV’s growth rate is therefore more likely to be stable to modest, unless specific regional reimbursement policies or clinical practice patterns favor injectables or older oral ester esters.

Practical forward projection (business-useful ranges)

For a conservative planning model suitable for an established molecule:

• Short term (0 to 12 months): flat to low growth driven by demographic baseline and replacement cycles
• Medium term (1 to 3 years): low single-digit CAGR in most mature markets unless a major formulary swing occurs
• Longer term (3 to 5 years): modest CAGR with continued pressure from transdermal and combination products

What are the R&D implications for an EV strategy now?

If a company is evaluating EV for new R&D spend, the value creation pathway is usually not “reinvent EV” clinically. It is typically:

• Formulation differentiation (improved dosing convenience, pharmacokinetic consistency)
• Regulatory re-positioning in specific subpopulations (where local labeling and access create commercial differentiation)
• Combination strategy (progestin pairing or HA/GAHT-adjacent positioning depending on jurisdiction)

In most cases, the clinical development burden is lower for line extensions, but the market advantage depends on reimbursement, formulary inclusion, and substitution dynamics.

How should you underwrite EV’s commercial outlook versus newer estrogen delivery systems?

A decision-grade underwriting approach separates:

1. Therapy-class demand (HRT and estrogen needs)
2. Share-of-route capture (injectable/oral esters vs transdermal)
3. Product-level constraints (patent situation, generics, distribution)
4. Safety/risk narrative impact (route and regimen influence)

Underwriting rule-of-thumb for EV

• Treat EV as a defensive revenue stream tied to established demand and local prescribing patterns.
• Assume margin compression as generics compete and as prescribers move toward transdermal routes.
• Value any incremental growth opportunity in EV around access levers (coverage, guideline inclusion, hospital formulary adoption).

Key Takeaways

• Estradiol valerate is best characterized as an established estrogen ester with incremental clinical activity rather than a late-stage pipeline molecule with recurring pivotal trial catalysts.
• Near-term upside is more likely to come from regulatory, reimbursement, and formulary inclusion than from major clinical breakthroughs.
• The medium-term market outlook is stable to modest growth in mature geographies, with substitution pressure from transdermal estradiol and estradiol combination products.
• Any strategy that depends on meaningful share gains from EV should underwrite route-shift headwinds and expect ongoing margin pressure from generic competition.

FAQs

1) Is estradiol valerate still generating meaningful Phase 3 trial readouts?

EV’s clinical activity is generally incremental and localized, with fewer decision-critical Phase 3 readouts compared with newer molecular or platform assets.

2) What is EV’s main therapeutic use profile?

EV is used as an estrogen for HRT-related indications and related estrogen therapy contexts, subject to country-specific approvals and labeling.

3) Does transdermal estradiol materially challenge EV?

Yes. Transdermal estradiol is a recurring substitution threat because route preferences and risk narratives often favor transdermal regimens in multiple guideline environments.

4) What drives EV growth in mature markets?

Demographics, baseline HRT access, and local prescribing and reimbursement patterns typically drive EV volume, with incremental gains limited by substitution.

5) What R&D angle is most realistic for value creation with EV?

Regulatory and commercial differentiation usually comes from formulation and access strategy rather than from large-scale new clinical efficacy programs.

---

References

[1] ClinicalTrials.gov. (n.d.). Search results for “estradiol valerate”. https://clinicaltrials.gov/
[2] U.S. FDA. (n.d.). Drug trials snapshots and labeling resources (estradiol products). https://www.fda.gov/
[3] EMA. (n.d.). European public assessment reports (estradiol ester products). https://www.ema.europa.eu/